How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Neuroendocrine Tumor(Net) Market
- By Tumor Type: Carcinoid Tumors, Pancreatic Neuroendocrine Tumors (PNETs), Medullary Thyroid Carcinoma, Merkel Cell Carcinoma, Paragangliomas
- By Treatment Modality: Surgical Resection, Somatostatin Analogues, Peptide Receptor Radionuclide Therapy (PRRT), Targeted Therapy (e.g., Everolimus, Sunitinib), Chemotherapy
- By Disease Stage: Localized, Locally Advanced, Metastatic
- By Diagnostic Method: Imaging Techniques (CT, MRI, PET), Biochemical Markers (Chromogranin A, 5-HIAA), Histopathological Examination, Molecular Profiling
- By Patient Demographics: Adult, Pediatric
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Carcinoid Tumors leads By Tumor Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Neuroendocrine Tumor(Net) Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Ipsen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Advanced Accelerator Applications (AAA) - a Novartis company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Ipsen Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Exelixis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Ipsen Biopharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Ipsen Pharma SAS
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Ipsen S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Ipsen Biopharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ipsen Pharma GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Ipsen Biopharmaceuticals Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Ipsen Biopharmaceuticals Pvt Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ipsen Biopharmaceuticals AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Carcinoid Tumors52.9
- Pancreatic Neuroendocrine Tumors (PNETs)12.3
- Medullary Thyroid Carcinoma8.3
- Merkel Cell Carcinoma9.4
- Paragangliomas17.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG21.1
- Ipsen12.6
- Advanced Accelerator Applications (AAA) - a Novartis company6.2
- Pfizer Inc.12.3
- Eli Lilly and Company5.8
- Ipsen Pharma14.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe23.1
- Asia Pacific21.9
- Latin America11.4
- Middle East and Africa8.9
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 87 | 73 | 96 | 92 | 90 | 78 | 86 |
| Ipsen | 81 | 84 | 90 | 72 | 76 | 91 | 82 |
| Advanced Accelerator Applications (AAA) - a Novartis company | 87 | 74 | 85 | 62 | 74 | 82 | 77 |
| Pfizer Inc. | 68 | 70 | 78 | 80 | 64 | 73 | 72 |
| Eli Lilly and Company | 61 | 74 | 53 | 57 | 55 | 77 | 63 |
| Ipsen Pharma | 52 | 63 | 50 | 69 | 55 | 65 | 59 |
| Exelixis Inc. | 47 | 50 | 54 | 51 | 51 | 56 | 52 |
| Ipsen Biopharmaceuticals | 52 | 42 | 56 | 38 | 60 | 47 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Ipsen
- Advanced Accelerator Applications (AAA) - a Novartis company
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Ipsen | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Advanced Accelerator Applications (AAA) - a Novartis company | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Pfizer Inc. | − | ◐ | ◐ | ✓ | − | ◐ |
| Eli Lilly and Company | − | ✓ | − | ◐ | ◐ | ✓ |
| Ipsen Pharma | ◐ | ◐ | ◐ | ✓ | − | ◐ |
| Exelixis Inc. | − | − | ◐ | − | − | − |
| Ipsen Biopharmaceuticals | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Tumor Type in North America, then scale across Neuroendocrine Tumor(Net) Market — a $497M beachhead inside a $6.50B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Carcinoid Tumors
Best fit — highest urgency & budget in Tumor Type.
Pancreatic Neuroendocrine Tumors (PNETs)
Strong fit — clear ROI and a fast path to value.
Medullary Thyroid Carcinoma
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Tumor Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Disease Stage
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Tumor Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Neuroendocrine Tumor(Net) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Neuroendocrine Tumor(Net) Market is a durable-growth opportunity — $1.93B by 2033, compounding at 7.9%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Tumor Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Tumor Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Neuroendocrine Tumor(Net) Market — a $5.99B market by 2033. Plan: grow share from 7.9% to 12.4%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 12.4% | At risk |
| Revenue | $475M | $743M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.4% | 38.4% | At risk |
| Customer retention | 90.7% | 95.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Tumor Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Tumor Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $105M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Tumor Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Sales deck · value proposition
Win the Neuroendocrine Tumor(Net) Market conversation — a $4.56B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Tumor Type
Goal Grow share in Tumor Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Neuroendocrine Tumor(Net) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Neuroendocrine Tumor(Net) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Neuro-Endovascular / Interventional Neurology Device Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportNeuroendovascular Coil and Non-Coil Devices Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportNeuroendovascular Non-Coil Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportNeurofibroma Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportNeurofibromatosis 10 mg Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportNeurofibromatosis 2 Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportNeurofibrosarcoma Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportNeuroimaging Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportNeurological Biomarker Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportNeurological intervention Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportNeurological Monitors Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportNeurological Physiotherapy Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy